StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Monday morning. The brokerage issued a sell rating on the medical technology company’s stock.

Several other equities research analysts have also commented on the stock. Benchmark restated a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a research report on Wednesday, October 2nd. Ascendiant Capital Markets decreased their price objective on shares of BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd.

BIOLASE Stock Performance

Shares of BIOLASE stock opened at $0.01 on Monday. BIOLASE has a one year low of $0.02 and a one year high of $1.94. The company has a market cap of $367,477.00, a P/E ratio of 0.00 and a beta of 0.67. The firm has a fifty day moving average of $0.01 and a two-hundred day moving average of $0.04.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.